Pipeline
Small Molecule Drug Conjugate (SMDC)
First-in-class, Precision Guided Cancer Therapy, could replace the original drug and suitable to combine with immunotherapy.
Drug Name Payload/MOA/Target Indication Rights Development Stage
Pre-clinical IND Phase I Phase II Phase III
Drug Name Payload/MOA/Target Indication Rights Pre-clinical IND Phase I Phase II Phase III
Precision Guided Chemo-Therapy
Drug Name Payload/MOA/Target Indication Rights Pre-clinical IND Phase I Phase II Phase III
QHL-108
(Legubicin)
Doxorubicin Soft Tissue Sarcoma Global
Lung Adenocarcinoma Global
Solid Tumor Global
QHL-236
(Legutaxel)
Paclitaxel Gastric Carcinoma Global
Solid Tumor Global
QHL-339 Platinum Solid Tumor Global
QHL-1618 TMEA-Dxd Solid Tumor Ex-Greater China
Precision Guided Target Therapy
Drug Name Payload/MOA/Target Indication Rights Pre-clinical IND Phase I Phase II Phase III
QHL-1231 AXL/VEGF/CMET Solid Tumor Global
QHL-718 VEGF/FGF Solid Tumor Global
QHL-506 PARPi Solid Tumor Global
QHL-625 CDK4/6 Solid Tumor Global
Precision Guided Immune Agonist
Drug Name Payload/MOA/Target Indication Rights Pre-clinical IND Phase I Phase II Phase III
QHL-1031 TLR7/8 Solid Tumor Global
QHL-816 Sting agonist Solid Tumor Global
   Registrational Clinical Trial
Biologics Conjugate
Best-In-Class Biologics including conjugate cytokines, antibodies and fusion proteins to create new generation drugs.
Drug Name Payload/MOA/Target Indication Rights Development Stage
Pre-clinical IND Phase I Phase II Phase III
Drug Name Payload/MOA/Target Indication Rights Pre-clinical IND Phase I Phase II Phase III
Drug Name Payload/MOA/Target Indication Rights Pre-clinical IND Phase I Phase II Phase III
IMD101 IL-2 Bladder Carcinoma Global
Solid Tumor Global
IMD303 CTLA-4 Solid Tumor Global
IMD-1005 CD47 Solid Tumor Global
IMD511 HER2-CD3 HER2-positive Breast Cancer Global
HER2-positive Gastric Cancer Global
IMD-917 DLL3-CD3 Solid Tumor Global
IMD-1618 CLDN6-CD3 Solid Tumor Global
IMD-605 GCC-CD3 Solid Tumor Global
IMD-2113 TAA-TLR7/8 (ADC) Solid Tumor Global
IMD-2316 TAA-Dxd (ADC) Solid Tumor Global
IMD-2739 TAA-Sting (ADC) Solid Tumor Global
Partners
Product (Partners) Molecule Rights Development Stage
Pre-clinical IND Phase I Phase II Phase III
Product (Partners) Molecule Rights Pre-clinical IND Phase I Phase II Phase III
Product (Partners) Molecule Rights Pre-clinical IND Phase I Phase II Phase III

I-MAB

Confidential Global
Confidential

Anglikang Pharmaceutical

QHL-1618 TMEA-Dxd Greater China

Partner

TMEA-ICE Global

Partner

TMEAbody Global

Partner

TMEA-SMDC Global
* Partners and collaborative details are not fully disclosed due to commercial sensitivity